MaaT Pharma logo

Initial Public Offering

€ 31.5 million
Joint Global Coordinator & Joint Bookrunner
;

MaaT Pharma

Joint Global Coordinator and Joint Bookrunner

Kempen & Co is pleased to announce that it acted as Joint Global Coordinator and Joint Bookrunner in MaaT Pharma’s €31.5 million Initial Public Offering

Transaction highlights

  • Initial Public Offering on the regulated market of Euronext Paris of 2,333,333 shares at a price of €13.50 per share, raising total gross proceeds of €31.5 million, which can increase to €36.2 million in case the over-allotment option is exercised in full
  • The transaction represents the biggest Life Sciences IPO on Euronext Paris in 2021YTD 
  • Kempen & Co extensively marketed the transaction towards a large group of domestic as well as international specialist and generalist institutional investors in the various marketing phases of the IPO
  • MaaT Pharma becomes the first publicly traded company developing microbiome-based drugs in continental Europe
  • The proceeds will primarily be used to fund the Phase III clinical trial evaluating lead product candidate MaaT013 for the treatment of graft-versus-host disease (GvHD), the initiation of a Phase II/III of MaaT033, and preparatory work for the Phase I of MaaT03X as well as the manufacturing scale-up of MaaT013, MaaT033 and MaaT03X
  • MaaT Pharma’s IPO marks the ninth Equity Capital Markets transaction on the regulated market of Euronext Paris in which Kempen & Co acted as an underwriter since 2015
  • Trading of MaaT Pharma’s shares on the regulated market of Euronext Paris under the symbol “MAAT” started on 8 November 2021
  • In 2021 year to date, Kempen & Co has executed 21 Equity Capital Markets transactions, totalling USD 2.3 billion, for European life sciences companies listed across Europe and in the US 

Company description

MaaT Pharma is a clinical-stage company with a well-established approach to restoring patient-microbiome symbiosis to improve survival outcomes in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients and completed a Phase II clinical trial. Their discovery and analysis platform, gutPrint®, supports the development and expansion of the company’s pipeline by determining novel disease targets, evaluating drug candidates and identifying biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to establish the utilization of microbiome treatment integration into clinical practice. The company is headquartered in Lyon, France. 

Background Kempen & Co Life Sciences & Healthcare

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Co-Manager in the USD 460 million Capital Increase by Ascendis Pharma 
  • Joint Bookrunner in the SEK 324 million Capital Increase by Calliditas Therapeutics
  • Joint Global Coordinator & Joint Bookrunner in the SEK 380 million Capital Increase by Xbrane Biopharma
  • Joint Global Coordinator in the €34.1m Capital Increase by Transgene
  • Joint Global Coordinator & Joint Bookrunner in the SEK 141 million Capital Increase by Immunicum
  • Lead Manager in the USD 63.8 million Nasdaq Initial Public Offering by Molecular Partners
  • Joint Bookrunner in the SEK 301 million Capital Increase by Q-linea
  • Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
  • Joint Bookrunner in the €30.0 million Capital Increase by GenSight Biologics
  • Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
  • Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
  • Joint Bookrunner in the SEK 1.11 billion Capital Increase by Oncopeptides
  • Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
  • Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
  • Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
  • Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
  • Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
  • Bookrunner in the USD 518 million US Public Offering by CureVac
  • Lead Manager in the USD 120 million US Public Offering by Merus 
  • Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
  • Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
  • Financial Adviser to DCprime in its merger with Immunicum 
  • Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics

Contact

Nadine Maalouf
Robin van Wijk

Transactions